{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:34:42Z","timestamp":1790271282445,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["RIE2025"],"award-info":[{"award-number":["RIE2025"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/OFLCG\/003\/2018"],"award-info":[{"award-number":["NMRC\/OFLCG\/003\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["OFLCG19May-0038"],"award-info":[{"award-number":["OFLCG19May-0038"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012415","name":"Biomedical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021516","name":"Social Justice Fund Northwest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"A*STAR Research Entities","doi-asserted-by":"publisher","award":["H23J2a0095"],"award-info":[{"award-number":["H23J2a0095"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"A*STAR Research Entities","doi-asserted-by":"publisher","award":["C210112003"],"award-info":[{"award-number":["C210112003"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"A*STAR Research Entities","doi-asserted-by":"publisher","award":["I22D1AG059"],"award-info":[{"award-number":["I22D1AG059"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"A*STAR Research Entities","doi-asserted-by":"publisher","award":["I2101E0001"],"award-info":[{"award-number":["I2101E0001"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ymthe.2024.09.025","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T17:41:35Z","timestamp":1727113295000},"page":"3895-3914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T\u00a0cells in humanized mice via PD-1 and TIGIT co-targeting"],"prefix":"10.1016","volume":"32","author":[{"given":"Wai Nam","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Harden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn Lu Wen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Jun Rou","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Yie","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Yee","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Karnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Wai Ho","family":"Shuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Chong","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng Gee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry Kok Yen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6437-1271","authenticated-orcid":false,"given":"Qingfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.09.025_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2024.09.025_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ijc.30463","article-title":"Cancer incidence and cancer control in Mongolia: Results from the National Cancer Registry 2008-12","volume":"140","author":"Chimed","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.09.025_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ymthe.2024.09.025_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ymthe.2024.09.025_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.09.025_bib6","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T\u00a0cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2024.09.025_bib7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.09.025_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2024.09.025_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib11","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.09.025_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib13","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I\/II Study","volume":"39","author":"Kelley","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib15","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1136\/gutjnl-2017-315201","article-title":"Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy","volume":"67","author":"Zhao","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ymthe.2024.09.025_bib16","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/hep.31812","article-title":"Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model","volume":"74","author":"Zhao","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2024.09.025_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.clim.2008.08.012","article-title":"Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients","volume":"129","author":"Cai","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib19","first-page":"17","article-title":"Diminished absolute counts of CD56dim and CD56bright natural killer cells in peripheral blood from Egyptian patients with hepatocellular carcinoma","volume":"16","author":"Fathy","year":"2009","journal-title":"Egypt. J. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/cmi.2014.91","article-title":"NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma","volume":"12","author":"Sun","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hep.23054","article-title":"Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor","volume":"50","author":"Hoechst","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2024.09.025_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082131","article-title":"Natural Born Killers: NK Cells in Cancer Therapy","volume":"12","author":"Franks","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.09.025_bib23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2017.00760","article-title":"NK Cell Exhaustion","volume":"8","author":"Bi","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.191.5.771","article-title":"Reversible defects in natural killer and memory CD8 T\u00a0cell lineages in interleukin 15-deficient mice","volume":"191","author":"Kennedy","year":"2000","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2024.09.025_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.smim.2014.01.010","article-title":"Tissue-resident natural killer cells and their potential diversity","volume":"26","author":"Sojka","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-032712-095921","article-title":"Human hemato-lymphoid system mice: current use and future potential for medicine","volume":"31","author":"Rongvaux","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2002-07-2024","article-title":"Human NK cell development in NOD\/SCID mice receiving grafts of cord blood CD34+ cells","volume":"102","author":"Kalberer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.09.025_bib28","doi-asserted-by":"crossref","first-page":"21783","DOI":"10.1073\/pnas.0912274106","article-title":"Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.09.025_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation in\u00a0vivo","volume":"206","author":"Huntington","year":"2009","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2024.09.025_bib30","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/s41422-021-00543-4","article-title":"Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity","volume":"31","author":"Guo","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2024.09.025_bib31","doi-asserted-by":"crossref","first-page":"E9626","DOI":"10.1073\/pnas.1705301114","article-title":"Humanized mouse model supports development, function, and tissue residency of human natural killer cells","volume":"114","author":"Herndler-Brandstetter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.09.025_bib32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1465-3249(05)70786-6","article-title":"IL-15: targeting CD8+ T\u00a0cells for immunotherapy","volume":"7","author":"Diab","year":"2005","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2024.09.025_bib34","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","article-title":"A pan-cancer single-cell panorama of human natural killer cells","volume":"186","author":"Tang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.09.025_bib35","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","article-title":"High-dimensional single-cell analysis of human natural killer cell heterogeneity","volume":"25","author":"Rebuffet","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib36","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1038\/s41467-019-11947-7","article-title":"Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome","volume":"10","author":"Yang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.09.025_bib37","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jhep.2022.05.020","article-title":"Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner","volume":"77","author":"Koh","year":"2022","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12967-023-04112-8","article-title":"Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma","volume":"21","author":"Chen","year":"2023","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ymthe.2024.09.025_bib39","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/JLB.4MR0620-091R","article-title":"Unraveling exhaustion in adaptive and conventional NK cells","volume":"108","author":"Merino","year":"2020","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T\u00a0cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib41","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jhep.2021.06.028","article-title":"Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"75","author":"Ma","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2147\/JHC.S464806","article-title":"LAYN Serves as a Prognostic Biomarker and Downregulates Tumor-Infiltrating CD8(+) T Cell Function in Hepatocellular Carcinoma","volume":"11","author":"Xiao","year":"2024","journal-title":"J.\u00a0Hepatocell. Carcinoma"},{"key":"10.1016\/j.ymthe.2024.09.025_bib43","article-title":"Immune Checkpoint Inhibitors in the Treatment of HCC","volume":"10","author":"Donisi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2024.09.025_bib45","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20204219","article-title":"A dual immune signature of CD8+ T\u00a0cells and MMP9 improves the survival of patients with hepatocellular carcinoma","volume":"41","author":"Ding","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ymthe.2024.09.025_bib46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T Cell Dysfunction in Cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2024.09.025_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41421-020-00214-5","article-title":"Global immune characterization of HBV\/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression","volume":"6","author":"Song","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.ymthe.2024.09.025_bib48","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1038\/s41467-021-24010-1","article-title":"Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma","volume":"12","author":"Ho","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.09.025_bib49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T\u00a0cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2024.09.025_bib50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/cmi.2015.115","article-title":"NKT cell subsets as key participants in liver physiology and pathology","volume":"13","author":"Bandyopadhyay","year":"2016","journal-title":"Cel. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib51","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2024.09.025_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194616","article-title":"Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma","volume":"14","author":"De Lorenzo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.09.025_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2024.09.025_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2024.09.025_bib55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-030-36667-4_5","article-title":"The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment","volume":"1231","author":"Neo","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40164-020-00192-0","article-title":"CD44 as a tumor biomarker and therapeutic target","volume":"9","author":"Xu","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib57","first-page":"475","article-title":"Matrix metalloproteinase 12 expression is associated with tumor FOXP3(+) regulatory T\u00a0cell infiltration and poor prognosis in hepatocellular carcinoma","volume":"16","author":"He","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ymthe.2024.09.025_bib58","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12876-021-01833-2","article-title":"Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma","volume":"21","author":"Lee","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ymthe.2024.09.025_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1154249","article-title":"Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments","volume":"5","author":"Cariani","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2024.09.025_bib60","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1038\/s41467-022-32283-3","article-title":"A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma","volume":"13","author":"Lu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.09.025_bib61","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/0008-5472.CAN-20-1885","article-title":"Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function","volume":"81","author":"La Fleur","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.09.025_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041025","article-title":"Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy","volume":"12","author":"Liu","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:29:49Z","timestamp":1783020589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624006117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1525001624006117"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.025","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T\u00a0cells in humanized mice via PD-1 and TIGIT co-targeting","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}